---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-007096"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T19:41:32.549322+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Virios receives Nasdaq deficiency notice for bid price; requests hearing to seek compliance extension

## Summary
- Second Nasdaq letter received May 1, 2024 for failure to maintain $1.00 minimum bid price.
- Initial 180-day compliance period expired April 30, 2024; company has requested a hearing to stay delisting.
- Plan to regain compliance includes IMC-2 Long-COVID study data from Bateman Horne Center and potential reverse stock split.
- Hearing before Nasdaq panel will determine extension; common stock (VIRI) remains listed pending decision.

## SEC filing metadata
- accession: 0001558370-24-007096
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837024007096/0001558370-24-007096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837024007096/tmb-20240501x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-007096
- JSON: https://secwatch.observer/filing/0001558370-24-007096.json
- Plain text: https://secwatch.observer/filing/0001558370-24-007096.txt

## Key facts
- Listing & Compliance Notices
  Dogwood Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price.
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  source text: May 1, 2024, we received another letter from Nasdaq informing us that our shares had failed to comply with the $1.00 minimum bid price required for continued listing. In accordance with the latest letter and established Nasdaq procedures, we have requested a hearing with Nasdaq, at which, we will seek to extend the period during which we will seek to regain compliance. Our request for such hearing has stayed the delisting of our common stock pending a Nasdaq hearings panel’s (the “Panel”) decision. We intend to present a plan to regain compliance to the Panel that includes a discussion of the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818844/000155837024007096/0001558370-24-007096-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.